Lack of pathologic down‐staging with neoadjuvant chemotherapy for muscle‐invasive urothelial carcinoma of the bladder
Abstract
BACKGROUND: The postcystectomy survival benefit associated with the combination of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) neoadjuvant chemotherapy (NC) for muscle‐invasive bladder cancer has been most evident in patients who achieve a pathologic complete response. The outcome of NC and open radical cystectomy (RC) was evaluated in a contemporary cohort of patients in a tertiary referral setting.METHODS: From January 2006 to November 2007, 117 patients underwent open RC at Cleveland Clinic for muscle‐invasive bladder cancer, 29 (25%) of whom received NC. Patient information was obtained from a prospective database.RESULTS: Clinical stage at the time of diagnosis in the NC cohort was T2 in 23 (79%) and T3‐4a in 6 (21%) patients. A total of 20 (69%) patients received the combination of gemcitabine and cisplatin (GC), 4 (14%) received MVAC, and 5 (17%) received other regimens. The median interval from the time of diagnosis of muscle‐invasive bladder cancer to RC was 208 days (interquartile range, 149 days ‐327 days) in the NC cohort. Overall, only 2 patients (7%; 95% confidence interval [95% CI], 0 patients‐17 patients) achieved a pathologic complete response, 18 (62%; 95% CI, 43 patients‐81 patients) had nonorgan‐confined residual cancer, and the overall median progression‐free survival was 10.5 months (95% CI, 7 months ‐14 months).CONCLUSIONS: Few RC patients in these investigators' recent experience achieved a pathologic complete response with NC, and most experienced rapid disease progression. These poor outcomes may be related to the use of non‐MVAC‐based regimens or excessive delay in performing RC. In the absence of supportive data for GC in the neoadjuvant setting, MVAC remained the preferred regimen. Excessive delays in performing RC may negate the benefit of NC. Cancer 2009. © 2009 American Cancer Society.Keywords
This publication has 27 references indexed in Scilit:
- Defining Optimal Therapy for Muscle Invasive Bladder CancerJournal of Urology, 2007
- Outcomes of Radical Cystectomy for Transitional Cell Carcinoma of the Bladder: A Contemporary Series From the Bladder Cancer Research ConsortiumJournal of Urology, 2006
- Neoadjuvant Chemotherapy in Invasive Bladder Cancer: Update of a Systematic Review and Meta-Analysis of Individual Patient DataEuropean Urology, 2005
- Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder CancerJournal of Clinical Oncology, 2005
- PROSPECTIVELY PACKAGED LYMPH NODE DISSECTIONS WITH RADICAL CYSTECTOMY: EVALUATION OF NODE COUNT VARIABILITY AND NODE MAPPINGJournal of Urology, 2004
- Extended Radical Lymphadenectomy in Patients With Urothelial Bladder Cancer:: Results of a Prospective Multicenter StudyJournal of Urology, 2004
- Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder CancerNew England Journal of Medicine, 2003
- Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysisThe Lancet, 2003
- AJCC Cancer Staging Manual2002
- Neoadjuvant cisplatin,methotrexate,and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trialThe Lancet, 1999